Cashu | Summary

DJI

+0.16%

SPX

+0.32%

IXIC

+0.53%

FTSE

-0.24%

N225

-0.26%

AXJO

-0.08%

HomeWatchlistNewsSignalsPicks

Stocks

0.00 (0.00%)

0.000

USD

At close at --,----

Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.

Company

About Us
Careers
Blog
News

Help & Support

Help Center
Contact Us
Pro Support

Legal

Instagram YouTube

HomeWatchlistNewsSignalsPicks

DJI

+0.16%

SPX

+0.32%

IXIC

+0.53%

FTSE

-0.24%

N225

-0.26%

AXJO

-0.08%

HomeWatchlistNewsSignalsPicks

Join our newsletter to keep up to date with us!

Stocks

0.00 (0.00%)

0.000

USD

At close at --,----

Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.

Company

About Us
Careers
Blog
News

Help & Support

Help Center
Contact Us
Pro Support

Legal

Instagram YouTube

Join our newsletter to keep up to date with us!

Overview

Loading chart...

Key Stats

Market Cap

111.82M

Dividend Yield

0.00%

P/E Ratio

-2.09

EPS

-1.27

Revenue

47.98M

Avg. Volume

293.30K

About

What does SPRO do?

Spero Therapeutics, based in Cambridge, Massachusetts, develops treatments for multi-drug resistant infections and rare diseases, with key products including SPR720, tebipenem HBr, and SPR206. The company went public on November 2, 2017, and employs 46 people.

Sector

💻 Health Care

IPO

CEO

Employees

Headquarters

Massachusetts, USA

Website

http://sperotherapeutics.com

Stocks

Health Care

spro